Abstract：
UNASSIGNED: The rise of biologic agents has been a major breakthrough in treating immune-mediated inflammatory diseases (IMIDs). However, their high cost underscores the need for strategies to optimize treatment efficiency. Biosimilars offer cost-effective alternatives to biologics. This study aimed to assess biosimilar drug availability\'s impact on biologic therapy access for IMIDs.
UNASSIGNED: A retrospective observational study in 15 Spanish hospitals analyzed IMID patients (arthropathies, inflammatory bowel disease and psoriasis) initiating biologic therapy with originator or biosimilar drugs (infliximab, etanercept, adalimumab). Time to availability and initiation of biologic therapy were assessed.
UNASSIGNED: 267 patients were included, with 58.4% starting on biosimilars. The mean time to availability of the biologic drugs in the hospitals was 15.9 ± 6.7 months, (20.0 ± 12.4 for originator and 11.8 ± 5.2 for biosimilars). Mean time to biologic treatment was 7.7 ± 9.0 years (8.6 ± 8.9 for originators and 7.0 ± 9.0 for biosimilars). Showing statistically significant differences among conditions.
UNASSIGNED: The emergence of biosimilar drugs has enhanced market competition and accelerated their adoption into hospitals\' therapeutic regimens over original reference drugs. This has significantly improved access to biologic therapy for patients with IMIDs, evidenced by a notable 1.6-year reduction in access time for biosimilar drugs.
UNASSIGNED: A retrospective observational study in 15 Spanish hospitals analyzed IMID patients (arthropathies, inflammatory bowel disease and psoriasis) initiating biologic therapy with originator or biosimilar drugs (infliximab, etanercept, adalimumab). Time to availability and initiation of biologic therapy were assessed.
UNASSIGNED: 267 patients were included, with 58.4% starting on biosimilars. The mean time to availability of the biologic drugs in the hospitals was 15.9 ± 6.7 months, (20.0 ± 12.4 for originator and 11.8 ± 5.2 for biosimilars). Mean time to biologic treatment was 7.7 ± 9.0 years (8.6 ± 8.9 for originators and 7.0 ± 9.0 for biosimilars). Showing statistically significant differences among conditions.
UNASSIGNED: The emergence of biosimilar drugs has enhanced market competition and accelerated their adoption into hospitals\' therapeutic regimens over original reference drugs. This has significantly improved access to biologic therapy for patients with IMIDs, evidenced by a notable 1.6-year reduction in access time for biosimilar drugs.
摘要：
■生物制剂的兴起已成为治疗免疫介导的炎性疾病（IMID）的重大突破。然而,它们的高成本强调了优化治疗效率的策略的必要性。生物仿制药提供了具有成本效益的生物制剂替代品。本研究旨在评估生物仿制药的可用性对IMID生物治疗的影响。
■在15家西班牙医院进行的回顾性观察研究分析了IMID患者（关节病，炎症性肠病和牛皮癣）使用原始药物或生物类似药物（英夫利昔单抗，依那西普,阿达木单抗）。评估生物治疗的可用时间和开始时间。
■267名患者被纳入，58.4%从生物仿制药开始。医院获得生物药物的平均时间为15.9±6.7个月，（发起人为20.0±12.4，生物仿制药为11.8±5.2）。生物治疗的平均时间为7.7±9.0年（鼻祖为8.6±8.9，生物仿制药为7.0±9.0）。显示条件之间的统计显着差异。
生物仿制药的出现增强了市场竞争，加速了它们在医院治疗方案中的应用，而不是原始参考药物。这显著改善了IMID患者获得生物治疗的机会，生物仿制药的使用时间显着减少了1.6年。
■在15家西班牙医院进行的回顾性观察研究分析了IMID患者（关节病，炎症性肠病和牛皮癣）使用原始药物或生物类似药物（英夫利昔单抗，依那西普,阿达木单抗）。评估生物治疗的可用时间和开始时间。
■267名患者被纳入，58.4%从生物仿制药开始。医院获得生物药物的平均时间为15.9±6.7个月，（发起人为20.0±12.4，生物仿制药为11.8±5.2）。生物治疗的平均时间为7.7±9.0年（鼻祖为8.6±8.9，生物仿制药为7.0±9.0）。显示条件之间的统计显着差异。
生物仿制药的出现增强了市场竞争，加速了它们在医院治疗方案中的应用，而不是原始参考药物。这显著改善了IMID患者获得生物治疗的机会，生物仿制药的使用时间显着减少了1.6年。
